News &

Press

venBio news

“venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies.”

“venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences.”

“venBio Closes $394 Million Life Sciences Venture Capital Fund.”

Portfolio news

Candid Therapeutics Debuts with $370M Capital Raise

Sep 9, 2024

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

Jul 23, 2024

Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction

Mar 6, 2024

Q&A: Ken Song details RayzeBio’s path from Series A to IPO in 3 years

Mar 5, 2024

Attralus Closes $56 Million Financing

Feb 8, 2024

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

Jan 29, 2024

35Pharma Announces Clearance of Clinical Trial Application for HS135, Best-in-Class Activin and GDF Inhibitor

Jan 11, 2024

San Francisco office

1700 Owens Street, Suite 595
San Francisco, CA 94158

Seattle office

1200 Westlake Ave N, Suite 900
Seattle, WA 98109

© 2024 venBio. All Rights Reserved.